BRLI Names New Medical Director to Oversee GenPath Cancer Laboratory.

Business Editors/High Tech & Health Writers

ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Sept. 7, 2000

Maria Pedemonte, MD, Will Lead Oncology Effort

Bio-Reference Laboratories, Inc (Nasdaq Small Cap-"BRLI"), has named Bader Maria Pedemonte-Coira, MD, to be Medical Director of Bio-Reference Laboratories and to oversee GenPath, the Company's Cancer Laboratory.

Dr. Pedemonte previously worked at Bio-Reference from 1996 to 1997 as Director of Immunohistochemistry. Her return as Medical Director signals a change in direction for Laboratory to emphasize specialized testing including oncology, immunology and genomic studies. As a pathologist who is Board Certified in both Hematopathology and Immunopathology, Dr. Pedemonte adds new dimension to the technical and scientific expertise of one of the top independent clinical laboratories in the country.

Dr. Pedemonte has previously worked at Impath, Inc and Quest Diagnostics (formerly Metpath Laboratories). In her previous stint at Bio-Reference, Dr. Pedemonte was Director for the GenCare division of Bio-Reference Laboratories where she oversaw the substantial growth of the laboratory's oncology business. In 1997, Bio-Reference sold that oncology business and Dr. Pedemonte followed the business unit to Impath.

In a statement, Dr. Pedemonte observed: "I am extremely excited to be back at Bio-Reference and I am particularly glad to be re-united with most of my former staff and colleagues. As Medical Director, I believe that I can add significant value to the Company's business. I have been given the challenge to expand the medical direction of the Laboratory and to help continue the tremendous growth that the Laboratory has been experiencing of late. These are the challenges that I have been seeking. The scientist in me welcomes the opportunity to lead the Bio-Reference effort in becoming a fully developed, fully competent, full service clinical laboratory. The entrepreneur in me thrills at the challenge of being part of the explosive growth of the business."

Marc Grodman, M.D., Chairman and CEO of BRLI, stated, "Maria Pedemonte combines her outstanding academic credentials with an insightful understanding of the clinical laboratory business. Her work and service ethic are rarely found in this business and we believe that her addition to the Senior Management team at Bio-Reference fortifies and defines our commitment to our clinical laboratory operations. The clinical lab business is no longer just a technical transaction business; it is truly a data information business. Most of our recent announcements have been about our CareEvolve division, our physician-centric eHealthcare connectivity portal solution. We believe, however, that naming Dr. Pedemonte Medical Director of the clinical laboratory should clearly indicate our continued focus on our core business and our desire to grow and expand the laboratory at the same time that we are diversifying the corporate strategy.

Dr. Grodman continued, "We have stated that our purpose in introducing and developing CareEvolve is to enable physicians to provide `Better Healthcare through Better Communication'. Our purpose in re-directing and re-focusing our core laboratory business is to enable physicians to provide `Better Healthcare through Better Information'. Simply put, Bio-Reference is dedicated to providing Better Healthcare and the appointment of Dr. Pedemonte as Medical Director is another major step towards our achieving that goal."

For additional information about BRLI, please visit www.bioreference.com, www.doctorny.com, www.drugscreenlab.com, www.drugabusekit.com, www.bioincubator.com, and www.rightbodyfoods.com.

BRLI is a multi-faceted Health Services and Information Company as well as the largest regional clinical laboratory in the North East United States. It has major market positions in physician offices, nursing homes and correctional institutions. Its toxicology division performs employee drug testing for major corporations nationwide, as well as for drug treatment centers and psychiatric hospitals. CareEvolve.com, a wholly owned subsidiary of BRLI, is a Physician based health portal that seeks to enhance physician-patient and physician-payer electronic communications on a secured basis, including communicating laboratory results, e-mail, prescriptions, payer verification and eligibility, as well as offering other Internet based services to its physician members. These services will be provided through an Internet connectivity backbone.

The Company's common stock is traded on the Nasdaq Small Cap system under the symbol "BRLI."

Statements included in this release that are not historical in nature, are intended to be, and are hereby identified as "forward-looking statements". Statements looking forward in time are included in this Annual Report pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to be materially different from any future performance suggested herein.